|
Pronunciation |
|
(fen
oks ee BEN za
meen) |
|
|
U.S. Brand
Names |
|
Dibenzyline® |
|
|
Generic
Available |
|
No |
|
|
Synonyms |
|
Phenoxybenzamine Hydrochloride |
|
|
Pharmacological Index |
|
Alpha1 Blockers |
|
|
Use |
|
Symptomatic management of pheochromocytoma; treatment of hypertensive crisis
caused by sympathomimetic amines |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Conditions in which a fall in blood pressure would be undesirable (eg,
shock) |
|
|
Warnings/Precautions |
|
Use with caution in patients with renal impairment, cerebral, or coronary
arteriosclerosis, can exacerbate symptoms of respiratory tract infections.
Because of the risk of adverse effects, avoid the use of this medication in the
elderly if possible. |
|
|
Adverse
Reactions |
|
>10%:
Cardiovascular: Postural hypotension, tachycardia, syncope
Ocular: Miosis
Respiratory: Nasal congestion
1% to 10%:
Cardiovascular: Shock
Central nervous system: Lethargy, headache, confusion, fatigue
Gastrointestinal: Vomiting, nausea, diarrhea, xerostomia
Genitourinary: Inhibition of ejaculation
Neuromuscular & skeletal: Weakness |
|
|
Overdosage/Toxicology |
|
Symptoms of overdose include hypotension, tachycardia, lethargy, dizziness,
shock
Hypotension and shock should be treated with fluids and by placing the
patient in the Trendelenburg position; only alpha-adrenergic pressors such as
norepinephrine should be used; mixed agents such as epinephrine, may cause more
hypotension |
|
|
Drug
Interactions |
|
Alpha adrenergic agonists decrease the effect of phenoxybenzamine.
Beta-blockers may result in increased toxicity (hypotension, tachycardia).
|
|
|
Mechanism of
Action |
|
Produces long-lasting noncompetitive alpha-adrenergic blockade of
postganglionic synapses in exocrine glands and smooth muscle; relaxes urethra
and increases opening of the bladder |
|
|
Pharmacodynamics/Kinetics |
|
Onset of action: Oral: Within 2 hours
Peak effect: Within 4-6 hours
Duration: Can continue for 4 or more days
Half-life: 24 hours
Elimination: Primarily in urine and feces |
|
|
Usual Dosage |
|
Oral:
Adults: Initial: 10 mg twice daily, increase by 10 mg every other day until
optimum dose is achieved; usual range: 20-40 mg 2-3 times/day
|
|
|
Dietary
Considerations |
|
Alcohol: Avoid use |
|
|
Administration |
|
GI irritation may be reduced by giving in divided doses |
|
|
Monitoring
Parameters |
|
Blood pressure, pulse, urine output, orthostasis |
|
|
Mental Health: Effects
on Mental Status |
|
May cause sedation, confusion, or dizziness |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
Concurrent use with low potency antipsychotics, TCAs and MAOIs may produce
additive hypotension |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
Avoid alcoholic beverages; if dizziness occurs, avoid sudden changes in
posture; may cause nasal congestion and constricted pupils; may inhibit
ejaculation; avoid cough, cold or allergy medications containing
sympathomimetics |
|
|
Nursing
Implications |
|
Monitor for orthostasis; assist with ambulation |
|
|
Dosage Forms |
|
Capsule, as hydrochloride: 10
mg |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|